Results 31 to 40 of about 31,699 (207)
, 2021 Due to limited treatment options for carbapenem-resistant Acinetobacter baumannii (CR-AB) infections, antibiotic combinations are now considered potential treatments for CR-AB.
Heffernan, AJ +3 more
core +1 more source
Antibiotics, 2019 This study assesses the synergistic effect of the combination of cephalosporins and sulbactam with daptomycin against daptomycin-nonsusceptible, vancomycin-intermediate resistant Staphylococcus aureus (VISA) or heterogeneous vancomycin-intermediate S ...
Chih-Cheng Lai +8 more
doaj +1 more source
The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 Despite the presence of more than 100 different antibacterials in the therapeutic arsenal, beta-lactam antibiotics, in general, and the third-generation cephalosporins, in particular, remain the main option for the treatment of the most of infections in ...
Stetsiouk O.U. +3 more
doaj +1 more source
Sulbactam/Durlobactam: First Approval
, 2023 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Susan Keam (4873372)
core +1 more source
Frontiers in Immunology, 2021 BackgroundABO blood type incompatibility hemolytic disease of newborn (ABO-HDN) and drug-induced immune hemolytic anemia (DIIHA) due to non-immunologic protein adsorption (NIPA) mainly cause extravascular hemolysis.
Yuanjun Wu +7 more
doaj +1 more source
, 2022 Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii.
Grace Ra (13024683) +9 more
core +1 more source
Pharmacokinetics of sulbactam in humans
Antimicrobial Agents and Chemotherapy, 1983 Sulbactam, a new beta-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin. Its half-life in humans is approximately 1 h. In a two-compartment pharmacokinetic model, the apparent volume of distribution for the central compartment is approximately 12 liters, and half of the dose is found in ...
G, Foulds +6 more
openaire +3 more sources
, 2020 The menace of multidrug resistance among bacterial infections is an issue of global public health. Treatment of these superbugs with first line antibiotics is associated with significant treatment failure leading to increased mortality and morbidity ...
Shalini Upadhyay +3 more
core +1 more source
-Lactamase Inhibition and In Vitro Activity of Sulbactam and Sulbactam/Cefoperazone [PDF]
Clinical Infectious Diseases, 1997 beta-Lactamase inhibitors such as sulbactam are beta-lactam compounds that have low antimicrobial activity but are able to inhibit enzymes (beta-lactamases) that destroy beta-lactam antibiotics like penicillins and cephalosporins. The main activity of beta-lactamase inhibitors is directed against plasmid-mediated transferable enzymes and various ...
openaire +2 more sources
, 2021 BackgroundABO blood type incompatibility hemolytic disease of newborn (ABO-HDN) and drug-induced immune hemolytic anemia (DIIHA) due to non-immunologic protein adsorption (NIPA) mainly cause extravascular hemolysis.
Yuanjun Wu (11865839) +6 more
core +1 more source